AbboMax腫瘤標(biāo)記物產(chǎn)品
AbboMax公司提供多種單克隆和多克隆抗體來(lái)對(duì)抗關(guān)鍵的腫瘤標(biāo)志物。
腫瘤生物標(biāo)志物是存在于腫瘤表面的物質(zhì),由腫瘤自身或宿主微環(huán)境產(chǎn)生。
它們是研究、腫瘤診斷和預(yù)后的有效工具。
我們?yōu)槟愕陌┌Y研究推薦幾種腫瘤標(biāo)記物。如下表:
Tumor Marker | Cancer Types |
AFP(Alpha fetoprotein) | Liver, ovarian, testicular cancer (germ cell) |
CEA | Colon, pancreatic, breast, ovarian, etc. |
Chromogranin A | Neuroendocrine tumors, colon cancer |
Estrogen receptor | Breast , cervical cancer |
Fibrinogen | Bladder, breast, endometrial cancer |
c-Kit | Gastrointestinal stromal tumor, acute myeloid leukemia, mucosal melanoma |
CD20 | Non-Hodgkin Lymphoma, majority of B-cell malignancies |
CD30 | Peripheral T-cell lymphoma, anaplastic large cell lymphoma, Hodgkin's lymphoma |
Cytokeratin-19 | Breast, bladder, lung carcinoma, etc. |
e-ErbB2 HER/Neu | Breast, ovarian, bladder, pancreatic, stomach cancers |
NSE | Small lung, neuroblastoma, endocrine tumors of the pancreas, melanoma |
Prostate Specific Antigen | Prostate cancer |
MMP-9 | Tumor metastasis in various cancers; gastric, giant cell tumor of bone, non-small lung cancer, cervical, ovarian, pancreatic, breast cancer, etc. |
Calcitonin | Thyroid cancer |
PCNA | Proliferation status of tumor tissues. Colorectal, breast, ovarian cancer, etc. |
KI-67 | Proliferation status of tumor tissues. Breast, ovarian, colorectal cancers, etc. |
EGFR | Prostate, liver, breast cancers, glioblastomas |
BRCA1 | Breast and ovarian cancers |
AbboMax腫瘤標(biāo)記物產(chǎn)品如下:
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
相關(guān)產(chǎn)品
免責(zé)聲明
- 凡本網(wǎng)注明“來(lái)源:化工儀器網(wǎng)”的所有作品,均為浙江興旺寶明通網(wǎng)絡(luò)有限公司-化工儀器網(wǎng)合法擁有版權(quán)或有權(quán)使用的作品,未經(jīng)本網(wǎng)授權(quán)不得轉(zhuǎn)載、摘編或利用其它方式使用上述作品。已經(jīng)本網(wǎng)授權(quán)使用作品的,應(yīng)在授權(quán)范圍內(nèi)使用,并注明“來(lái)源:化工儀器網(wǎng)”。違反上述聲明者,本網(wǎng)將追究其相關(guān)法律責(zé)任。
- 本網(wǎng)轉(zhuǎn)載并注明自其他來(lái)源(非化工儀器網(wǎng))的作品,目的在于傳遞更多信息,并不代表本網(wǎng)贊同其觀點(diǎn)和對(duì)其真實(shí)性負(fù)責(zé),不承擔(dān)此類作品侵權(quán)行為的直接責(zé)任及連帶責(zé)任。其他媒體、網(wǎng)站或個(gè)人從本網(wǎng)轉(zhuǎn)載時(shí),必須保留本網(wǎng)注明的作品第一來(lái)源,并自負(fù)版權(quán)等法律責(zé)任。
- 如涉及作品內(nèi)容、版權(quán)等問題,請(qǐng)?jiān)谧髌钒l(fā)表之日起一周內(nèi)與本網(wǎng)聯(lián)系,否則視為放棄相關(guān)權(quán)利。